Immuno-oncology assay market predicted to be worth $6bn by 2026
A rise in biotechnology R&D activities is expected to drive the growth of the immuno-oncology assay market, with a CAGR of 10.6 percent.
List view / Grid view
A rise in biotechnology R&D activities is expected to drive the growth of the immuno-oncology assay market, with a CAGR of 10.6 percent.
An antibody that neutralises both SARS-CoV and SARS-CoV-2 in cell cultures has been discovered by researchers and could be used to treat COVID-19.
High-resolution mass spectrometry has been used by researchers to map the glycan-processing states of the Spike protein of the SARS-CoV-2 virus, which causes COVID-19.
According to a new study, treatments for COVID-19 should focus on cytokines and T-cell counts and their function, rather than patient respiratory function.
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
Scientists have developed a new antimicrobial peptide therapy named D8 with high efficacy and low toxicity in mice which could be used to fight lung infections.
A group of researchers has used cryo-EM to discover the structure of the remdesivir-bound RNA complex of SARS-CoV-2 and explain how the drug inhibits COVID-19 viral replication.
By culturing blood cells with mesenchymal stromal cells (MSCs), researchers induced the production of cells with the same functionality as Tregs.
Researchers have uncovered the structure of nonribosomal peptide synthetases (NRPSs), an important ingredient in drug production.
According to researchers, ACE2 receptors disappear from lung cells during COVID-19, allowing small blood vessels to leak at the site of infection, presenting a new drug target.
Bringing together protein science, drug discovery experience and innovative technology, a new collaboration aims to identify novel drug targets for COVID-19.
A new study has revealed that the presence of soil in wounds helps to activate a blood protein known as coagulation Factor XII, leading to clotting.
Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
A novel software made by scientists can be used for the analysis of specific lipid groups and lipid signal molecules which can enable their characterisation with mass spectrometry.
A new AI tool has been created by researchers to identify the best treatment courses and doses for bacterial or viral infections, such as COVID-19.